


Introduction

Jason A. Efstathiou



www.elsevier.com/locate/enganabound

PII: S1053-4296(16)30048-0

DOI: <http://dx.doi.org/10.1016/j.semradonc.2016.10.001>

Reference: YSRAO50571

To appear in: *Seminars in Radiation Oncology*

Cite this article as: Jason A. Efstathiou, Introduction, *Seminars in Radiation Oncology*, <http://dx.doi.org/10.1016/j.semradonc.2016.10.001>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Jason A. Efstathiou, MD, DPhil  
Associate Professor  
Harvard Medical School  
Director, Genitourinary Division  
Department of Radiation Oncology  
Massachusetts General Hospital  
100 Blossom Street, Cox 3  
Boston, MA USA  
Ph: 617-726-5866; Fax: 617-726-3603  
jefstathiou@partners.org

#### Disclosures

Advisory Board: Genentech, Medivation/Astellas  
Joint Scientific Review Committee: Bayer Healthcare

#### Introduction

The landscape of prostate cancer and its management has undergone significant changes over the past decade. Notably, there has been a decrease in the utilization of PSA screening since such testing was offered a Grade D recommendation by the United States Preventative Services Task Force (USPSTF) guidelines in late 2011<sup>1</sup>. As a result, large observational database studies have suggested a relative decrease in incident prostate cancer and low-risk disease in the US<sup>1</sup>. There has also been a shift in management towards active surveillance for lower-risk disease and radical prostatectomy for higher-risk disease, seemingly at the expense of radiation<sup>2,3</sup>. While active surveillance helps to address the phenomenon of overtreatment and is supported by strong data for low and low-intermediate prostate cancer<sup>4,5</sup>, the encroachment of surgery into high-risk disease has not necessarily been supported by robust evidence as much as devout beliefs<sup>6,7</sup>. As a consequence, many radiation oncologists have noticed that their prostate cancer practice has shifted in emphasis from treating definitive intact cases towards seeing and treating more and more patients for postoperative indications (pathologic T3, positive margins, nodal involvement and/or biochemical recurrence) when surgery has probably failed

Download English Version:

<https://daneshyari.com/en/article/5579467>

Download Persian Version:

<https://daneshyari.com/article/5579467>

[Daneshyari.com](https://daneshyari.com)